Oak Ridge Investments LLC Buys 802 Shares of Eli Lilly and Company $LLY

Key Points

• Oak Ridge Investments LLC has increased its stake in Eli Lilly and Company by 1.4%, now owning 59,415 shares valued at approximately $46.3 million, making it the 7th largest position in their portfolio.
• Various hedge funds have significantly modified their positions in Eli Lilly, with PNC Financial Services boosting its stake by 97.5% during the first quarter, acquiring over 50 million shares.
• Eli Lilly reported a strong earnings performance with an EPS of $6.31 for the last quarter, exceeding analysts' estimates of $5.59, alongside a revenue of $15.56 billion, reflecting a year-over-year growth of 37.6%.

Oak Ridge Investments LLC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 59,415 shares of the company's stock after buying an additional 802 shares during the quarter. Eli Lilly and Company accounts for about 3.3% of Oak Ridge Investments LLC's holdings, making the stock its 7th biggest position. Oak Ridge Investments LLC's holdings in Eli Lilly and Company were worth $46,316,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of LLY. PNC Financial Services Group Inc. boosted its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after buying an additional 81,587 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock worth $4,808,443,000 after buying an additional 682,203 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity

In other news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. Corporate insiders own 0.13% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the stock an "overweight" rating in a report on Thursday. Leerink Partners reissued a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $948.56.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $833.08 on Friday. The company has a 50-day moving average of $742.42 and a 200-day moving average of $765.94. The company has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.